Inhibition of HMOX1 alleviates diabetic cardiomyopathy by targeting ferroptosis DOI Creative Commons
Huiping Yang, Guodong Xiao, Dinghui Wang

и другие.

Acta Biochimica et Biophysica Sinica, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Diabetic cardiomyopathy (DCM) is an important complication of chronic diabetes mellitus. However, its pathologic process and pathogenesis have not been fully elucidated. This study aims to investigate the role ferroptosis in DCM clarify effect heme oxygenase-1 (HMOX1) on by targeting ferroptosis. In vivo, animal model established subjecting mice a high-fat diet (HFD) combined with low-dose streptozotocin (STZ) injection. We induce vitro exposing H9C2 cells high glucose palmitic acid. Transcriptome sequencing reveals that differentially expressed genes (DEGs) are enriched primarily fatty acid metabolism mitochondrial β-oxidation, which closely related The experimental results show diabetic microenvironment induces both vivo vitro. Western blot analysis decreased expressions antioxidant proteins GPX4, SLC7A11 ferritin group. qPCR demonstrates elevated markers PTGS2 ACSL4. Biochemical indicators further support occurrence ferroptosis, increased levels malondialdehyde (MDA) lactate dehydrogenase (LDH), along level glutathione (GSH). vitro, intervention reversed ferrostatin-1 (Fer-1). Results expression HMOX1 DCM. Moreover, knockdown ameliorates thereby alleviating reducing cardiac fibrosis improving function. Our elucidates HMXO1 provides potential therapeutic strategy for clinical treatment.

Язык: Английский

Progress in the treatment of diabetic cardiomyopathy, a systematic review DOI Creative Commons
Yiyi Shou, X M Li, Quan Fang

и другие.

Pharmacology Research & Perspectives, Год журнала: 2024, Номер 12(2)

Опубликована: Фев. 26, 2024

Diabetic cardiomyopathy (DCM) is a condition characterized by myocardial dysfunction that occurs in individuals with diabetes, the absence of coronary artery disease, valve and other conventional cardiovascular risk factors such as hypertension dyslipidemia. It considered significant consequential complication diabetes field medicine. The primary pathological manifestations include hypertrophy, fibrosis, impaired ventricular function, which can lead to widespread necrosis. Ultimately, this progress development heart failure, arrhythmias, cardiogenic shock, severe cases even resulting sudden cardiac death. Despite several decades both fundamental clinical research conducted globally, there are currently no specific targeted therapies available for DCM practice, incidence mortality rates failure remain persistently high. Thus, article provides an overview current treatment modalities novel techniques pertaining DCM, aiming offer valuable insights support researchers dedicated investigating complex condition.

Язык: Английский

Процитировано

9
Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives DOI Creative Commons
Elina Khattab,

Michaelia Kyriakou,

Elena Leonidou

и другие.

Pharmaceuticals, Год журнала: 2025, Номер 18(1), С. 134 - 134

Опубликована: Янв. 20, 2025

Diabetes mellitus (DM) is a multifaceted disorder with pandemic spread and remarkable burden of cardiovascular mortality morbidity. Diabetic cardiomyopathy (DBCM) has been increasingly recognized as the development cardiac dysfunction, which accompanied by heart failure (HF) symptoms in absence obvious reasons like ischemic disease, hypertension, or valvulopathies. Several pathophysiological mechanisms have proposed, including metabolic disorders (e.g., glycation products), oxidative stress, low-grade inflammation, mitochondrial etc., should guide new therapeutic strategies. Up to now, HF treatment not differed between patients without diabetes, limits expected benefits despite high risk former group. However, DBCM may require different management, prioritize anti-diabetic medications testing other novel therapies. This review aims appraise challenges prospectives individualized pharmaceutical therapy for DBCM.

Язык: Английский

Процитировано

0
L-Arginine: A multifaceted regulator of diabetic cardiomyopathy DOI
Muskan Thakur, Rashmi S. Tupe

Biochemical and Biophysical Research Communications, Год журнала: 2025, Номер unknown, С. 151720 - 151720

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Diabetic cardiomyopathy: Emerging therapeutic options DOI
Cornelius James Fernandez, Sahana Shetty, Joseph M. Pappachan

и другие.

World Journal of Diabetes, Год журнала: 2024, Номер 15(8), С. 1677 - 1682

Опубликована: Июль 25, 2024

Diabetic cardiomyopathy (DbCM) is a common but underrecognized compli-cation of patients with diabetes mellitus (DM). Although the pathobiology other cardiac complications such as ischemic heart disease and autonomic neuropathy are mostly known reasonable therapeutic options, mechanisms management options for DbCM still not fully understood. In its early stages, presents diastolic dysfunction followed by failure (HF) preserved ejection fraction that can progress to systolic HF reduced in advanced stages unless appropriately managed. Apart from prompt control DM lifestyle changes antidiabetic medications, disease-modifying therapy includes hypertension dyslipidemia inherent forms diseases use treatments proven efficacy HF. A basic study Zhang

Язык: Английский

Процитировано

2
DIABETES MELLITUS E DOENÇAS CARDIOVASCULARES: MANIFESTAÇÕES CLÍNICAS E ESTRATÉGIAS DE TRATAMENTO DOI Creative Commons

L Goncalves,

Letícia de Mariz Moura,

Marina Gabriela de Almeida Arantes

и другие.

Revista Ibero-Americana de Humanidades, Ciências e Educação, Год журнала: 2024, Номер 10(6), С. 1992 - 2001

Опубликована: Июнь 11, 2024

A intersecção entre Diabetes Mellitus (DM) e doenças cardiovasculares (DCV) é um campo de estudo vital na medicina, dada a prevalência crescente ambas as condições sua associação com morbidade mortalidade significativas. O DM, caracterizado por disfunção metabólica, está intrinsecamente ligado ao desenvolvimento progressão DCVs, como doença arterial coronariana, acidente vascular cerebral insuficiência cardíaca. As manifestações clínicas podem variar complicações macrovasculares microvasculares, resultando em uma carga substancial para o paciente sistema saúde. Estratégias tratamento multifacetadas são necessárias mitigar os riscos associados incluindo controle glicêmico rigoroso, manejo da pressão lipídios, além intervenções comportamentais farmacológicas. Objetivo: Realizar revisão sistemática literatura avaliar relações cardiovasculares, analisando clínicas, estratégias eficácia, base evidências científicas dos últimos 10 anos. Metodologia: Para conduzir esta sistemática, seguimos protocolo do checklist PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) garantir transparência qualidade processo. Inicialmente, realizamos buscas nas bases dados PubMed, Scielo Web of Science, utilizando descritores "Diabetes Mellitus", "doenças cardiovasculares", "manifestações clínicas", "tratamento" "estratégias". Esses termos foram selecionados abranger aspectos-chave relação diabetes foco estudos publicados nos Os critérios inclusão estipularam que artigos deveriam abordar diretamente humanos, estar disponíveis inglês ter sido 2014 data pesquisa. Por outro lado, excluídos não estavam relacionados tema, ou antes 2014. Resultados: destacou forte DM DCV, variadas, aterosclerose, nefropatia diabética neuropatia autonômica. eficazes incluíram intensivo, uso estatinas inibidores SGLT2, no estilo vida. No entanto, desafios persistem prevenção das DM. Conclusão: reforça importância vigilância intervenção precoce interseção destacando necessidade abordagens multidisciplinares personalizadas otimizar resultados clínicos reduzir global pacientes

Процитировано

1
Desafios no diagnóstico e manejo do paciente com miocardiopatia diabética DOI Open Access

J. D. A. OLIVEIRA,

Ana Luiza Jaquel Corrêa,

Camila Guidi Rossi

и другие.

Brazilian Journal of Health Review, Год журнала: 2024, Номер 7(4), С. e71325 - e71325

Опубликована: Июль 19, 2024

O presente trabalho teve por objetivo descrever, a partir de uma revisão narrativa literatura, como é realizado o diagnóstico e manejo do paciente com miocardiopatia diabética. Sabe-se que diabética patologia multifatorial na qual miocárdio sofre alterações estruturais funcionais decorrentes da Diabetes Mellitus. deve ser feito à análise destas no ecocardiograma, assim avaliação das manifestações clínicas relacionadas alteração funções sistólica diastólica coração, em um não apresenta doença arterial coronariana significativa, valvulopatias, doenças cardíacas congênitas, hipertensão dislipidemia, associadas presença Vale ressaltar prevenção evolução está intimamente relacionada precocidade diagnóstico. duas vertentes, sendo indicada realização tratamento farmacológico associado terapia medicamentosa. primeiro inclui mudanças estilo vida, prática exercícios físicos dieta para controle hiperglicemia, enquanto segundo se baseia uso diversas classes farmacológicas, os fármacos mais associados melhor prognóstico metformina, inibidores enzima conversora angiotensina betabloqueadores

Процитировано

0
The role of NF-κB in diabetic cardiomyopathy DOI Creative Commons

Huang-Jun Liu,

Le-Kun Gui, Wei Han

и другие.

All Life, Год журнала: 2024, Номер 17(1)

Опубликована: Сен. 5, 2024

Язык: Английский

Процитировано

0
Fabrication of osmotic pump tablets utilizing semisolid extrusion three-dimensional printing technology DOI
Hao Chen, Dongyang Fang, Xiangyu Wang

и другие.

International Journal of Pharmaceutics, Год журнала: 2024, Номер 665, С. 124668 - 124668

Опубликована: Сен. 6, 2024

Язык: Английский

Процитировано

0
Inhibition of HMOX1 alleviates diabetic cardiomyopathy by targeting ferroptosis DOI Creative Commons
Huiping Yang, Guodong Xiao, Dinghui Wang

и другие.

Acta Biochimica et Biophysica Sinica, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Diabetic cardiomyopathy (DCM) is an important complication of chronic diabetes mellitus. However, its pathologic process and pathogenesis have not been fully elucidated. This study aims to investigate the role ferroptosis in DCM clarify effect heme oxygenase-1 (HMOX1) on by targeting ferroptosis. In vivo, animal model established subjecting mice a high-fat diet (HFD) combined with low-dose streptozotocin (STZ) injection. We induce vitro exposing H9C2 cells high glucose palmitic acid. Transcriptome sequencing reveals that differentially expressed genes (DEGs) are enriched primarily fatty acid metabolism mitochondrial β-oxidation, which closely related The experimental results show diabetic microenvironment induces both vivo vitro. Western blot analysis decreased expressions antioxidant proteins GPX4, SLC7A11 ferritin group. qPCR demonstrates elevated markers PTGS2 ACSL4. Biochemical indicators further support occurrence ferroptosis, increased levels malondialdehyde (MDA) lactate dehydrogenase (LDH), along level glutathione (GSH). vitro, intervention reversed ferrostatin-1 (Fer-1). Results expression HMOX1 DCM. Moreover, knockdown ameliorates thereby alleviating reducing cardiac fibrosis improving function. Our elucidates HMXO1 provides potential therapeutic strategy for clinical treatment.

Язык: Английский

Процитировано

0